Q32 Bio Inc. Files 8-K for December 10, 2024 Events

Ticker: QTTB · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1661998

Q32 Bio Inc. 8-K Filing Summary
FieldDetail
CompanyQ32 Bio Inc. (QTTB)
Form Type8-K
Filed DateDec 11, 2024
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Q32 Bio filed an 8-K on Dec 11 for Dec 10 events - check for Reg FD, other news, and financials.

AI Summary

Q32 Bio Inc. filed an 8-K on December 11, 2024, reporting on events that occurred on December 10, 2024. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Homology Medicines, Inc., is incorporated in Delaware and headquartered in Waltham, Massachusetts.

Why It Matters

This 8-K filing provides important updates and disclosures from Q32 Bio Inc. regarding recent events and financial information, which are crucial for investors to understand the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediate negative news or significant risk factors.

Key Players & Entities

  • Q32 Bio Inc. (company) — Registrant
  • Homology Medicines, Inc. (company) — Former company name
  • December 10, 2024 (date) — Date of earliest event reported
  • December 11, 2024 (date) — Filing date
  • Waltham, Massachusetts (location) — Principal executive offices location

FAQ

What is the primary purpose of this 8-K filing for Q32 Bio Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits that occurred on or around December 10, 2024.

When was this 8-K filed with the SEC?

This 8-K was filed with the SEC on December 11, 2024.

What was Q32 Bio Inc.'s former name?

Q32 Bio Inc.'s former name was Homology Medicines, Inc.

Where are Q32 Bio Inc.'s principal executive offices located?

Q32 Bio Inc.'s principal executive offices are located at 830 Winter Street, Waltham, Massachusetts, 02451.

What is the Commission File Number for Q32 Bio Inc.?

The Commission File Number for Q32 Bio Inc. is 001-38433.

Filing Stats: 1,810 words · 7 min read · ~6 pages · Grade level 13.8 · Accepted 2024-12-11 07:00:36

Key Financial Figures

  • $0.0001 — ich registered Common stock, par value $0.0001 per share QTTB The Nasdaq Global Ma

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws,. Any statements contained herein which do not describe historical facts, including, among others, our beliefs, observations, expectations and assumptions regarding the topline data from the SIGNAL-AA Phase 2a and the safety, tolerability, clinical activity including biomarker data, potential efficacy and potential benefits of bempikibart; plans and expectations for Part B of the SIGNAL-AA Phase 2a clinical trial are forward-looking statements, which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support our current beliefs and expectations for bempikibart; future clinical studies, including the Part B of the SIGNAL-AA Phase 2a clinical trial, may not be completed in a timely manner or at all, might be more costly than expected or might not yield anticipated results, the Company may need additional funding to complete its clinical studies, which may not be available on favorable terms or at all, and such other risks and uncertainties identified in th

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release issued by Q32 Bio Inc. on December 10, 2024 99.2 Corporate deck, dated as of December 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Q32 BIO INC. Date: December 11, 2024 By: /s/ Jodie Morrison Name: Title: Jodie Morrison Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.